Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.48 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 2/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869552 | 0.98 | EGFR (0.52) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869707 | 0.95 | EGFR (0.54) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869769 | 0.94 | EGFR (0.53) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869886 | 0.92 | EGFR (0.46) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869573 | 0.92 | EGFR (0.53) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869570 | 0.91 | EGFR (0.52) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869773 | 0.90 | EGFR (0.45) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869734 | 0.90 | EGFR (0.55) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869481 | 0.89 | EGFR (0.44) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL30869484 | 0.88 | EGFR (0.49) | EGFRMAP4K4ERBB2MAPK9CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | EGFR 1355/4885MAP4K4 2161/4885ERBB2 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.